研究园简易版 · 经典书籍 · 期刊文章 · 有原文 · 完整版(可多选筛选、搜索) · 首页
2020 年 · Clinical Trials(临床试验)
116 篇,新的在前。点标题看作者和摘要。回到 2020 年
- Robust Wald‐type tests under random censoring · SiM · 2020-12-28 · 在第 1 页
- A group sequential design and sample size estimation for an immunotherapy trial with a delayed treatment effect · SMMR · 2020-12-23 · 在第 1 页
- CWL: A conditional weighted likelihood method to account for the delayed joint toxicity–efficacy outcomes for phase I/II clinical trials · SMMR · 2020-12-21 · 在第 1 页
- Power and sample size for observational studies of point exposure effects · Biometrics · 2020-12-18 · 在第 1 页
- Probability intervals of toxicity and efficacy design for dose-finding clinical trials in oncology · SMMR · 2020-12-16 · 在第 1 页
- Estimation of ascertainment bias and its effect on power in clinical trials with time‐to‐event outcomes · SiM · 2020-12-14 · 在第 2 页
- Mean comparisons and power calculations to ensure reproducibility in preclinical drug discovery · SiM · 2020-12-09 · 在第 2 页
- A note on estimating the Cox‐Snell R 2 from a reported C statistic ( AUROC ) to inform sample size calculations for developing a prediction model with a binary outcome · SiM · 2020-12-07 · 在第 2 页
- Statistical design considerations for trials that study multiple indications · SMMR · 2020-12-02 · 在第 2 页
- Efficient and flexible simulation-based sample size determination for clinical trials with multiple design parameters · SMMR · 2020-12-02 · 在第 2 页
- Design and analysis of three‐arm parallel cluster randomized trials with small numbers of clusters · SiM · 2020-11-30 · 在第 3 页
- Bayesian adaptive decision-theoretic designs for multi-arm multi-stage clinical trials · SMMR · 2020-11-26 · 在第 3 页
- Adaptive enrichment trials: What are the benefits? · SiM · 2020-11-26 · 在第 3 页
- Small sample sizes: A big data problem in high-dimensional data analysis · SMMR · 2020-11-24 · 在第 3 页
- Employing a latent variable framework to improve efficiency in composite endpoint analysis · SMMR · 2020-11-24 · 在第 4 页
- Bayesian methods to compare dose levels with placebo in a small n, sequential, multiple assignment, randomized trial · SiM · 2020-11-20 · 在第 4 页
- A unified approach to sample size and power determination for testing parameters in generalized linear and time‐to‐event regression models · SiM · 2020-11-18 · 在第 4 页
- Balancing Unobserved Covariates With Covariate-Adaptive Randomized Experiments · JASA · 2020-11-12 · 在第 4 页
- Two‐stage randomized trial design for testing treatment, preference, and self‐selection effects for count outcomes · SiM · 2020-11-10 · 在第 4 页
- Propensity score weighting for covariate adjustment in randomized clinical trials · SiM · 2020-11-10 · 在第 4 页
- Minimum sample size for external validation of a clinical prediction model with a continuous outcome · SiM · 2020-11-04 · 在第 5 页
- Net benefit in the presence of correlated prioritized outcomes using generalized pairwise comparisons: A simulation study · SiM · 2020-11-02 · 在第 5 页
- Assessing consistency in clinical trials with two subgroups and binary endpoints: A new test within the logistic regression model · SiM · 2020-10-26 · 在第 6 页
- A framework for considering the risk‐benefit trade‐off in designing noninferiority trials using composite outcome approaches · SiM · 2020-10-26 · 在第 6 页
- A Bayesian adaptive phase I/II platform trial design for pediatric immunotherapy trials · SiM · 2020-10-22 · 在第 6 页
- A parsimonious personalized dose-finding model via dimension reduction · Biometrika · 2020-10-20 · 在第 6 页
- Sample size and sample composition for constructing growth reference centiles · SMMR · 2020-10-12 · 在第 6 页
- Improving precision and power in randomized trials for COVID‐19 treatments using covariate adjustment, for binary, ordinal, and time‐to‐event outcomes · Biometrics · 2020-10-11 · 在第 6 页
- Nonparametric cluster significance testing with reference to a unimodal null distribution · Biometrics · 2020-10-06 · 在第 7 页
- Net benefit index: Assessing the influence of a biomarker for individualized treatment rules · Biometrics · 2020-09-24 · 在第 8 页
- Comparison of small-sample standard-error corrections for generalised estimating equations in stepped wedge cluster randomised trials with a binary outcome: A simulation study · SMMR · 2020-09-24 · 在第 8 页
- Bayesian adaptive N‐of‐1 trials for estimating population and individual treatment effects · SiM · 2020-09-24 · 在第 8 页
- A proportional risk model for time-to-event analysis in randomized controlled trials · SMMR · 2020-09-22 · 在第 8 页
- Survival analysis using a 5‐step stratified testing and amalgamation routine (5‐STAR) in randomized clinical trials · SiM · 2020-09-20 · 在第 8 页
- Optimal two-stage sampling for mean estimation in multilevel populations when cluster size is informative · SMMR · 2020-09-17 · 在第 9 页
- Design for immuno‐oncology clinical trials enrolling both responders and nonresponders · SiM · 2020-09-17 · 在第 9 页
- A simulation‐free approach to assessing the performance of the continual reassessment method · SiM · 2020-09-16 · 在第 9 页
- Estimating the sample variance from the sample size and range · SiM · 2020-09-15 · 在第 9 页
- A batch‐effect adjusted Simon's two‐stage design for cancer vaccine clinical studies · Biometrics · 2020-09-10 · 在第 9 页
- Understanding between-cluster variation in prevalence and limits for how much variation is plausible · SMMR · 2020-09-09 · 在第 9 页
- Score confidence intervals and sample sizes for stratified comparisons of binomial proportions · SiM · 2020-09-09 · 在第 9 页
- Bayesian enhancement two‐stage design with error control for phase II clinical trials · SiM · 2020-08-27 · 在第 10 页
- BILITE: A Bayesian randomized phase II design for immunotherapy by jointly modeling the longitudinal immune response and time‐to‐event efficacy · SiM · 2020-08-27 · 在第 10 页
- Inference on a New Class of Sample Average Treatment Effects · JASA · 2020-08-25 · 在第 11 页
- Sample size requirements for detecting treatment effect heterogeneity in cluster randomized trials · SiM · 2020-08-21 · 在第 11 页
- Blinded continuous information monitoring of recurrent event endpoints with time trends in clinical trials · SiM · 2020-08-19 · 在第 11 页
- Variance formulae for multiphase stepped wedge cluster randomized trial · SiM · 2020-08-17 · 在第 11 页
- An Information Theoretic Approach for Selecting Arms in Clinical Trials · JRSSB · 2020-08-16 · 在第 11 页
- A Bayesian time‐to‐event pharmacokinetic model for phase I dose‐escalation trials with multiple schedules · SiM · 2020-08-14 · 在第 11 页
- Incorporating pragmatic features into power analysis for cluster randomized trials with a count outcome · SiM · 2020-08-10 · 在第 12 页
- Group sequential designs for clinical trials with bivariate endpoints · SiM · 2020-08-10 · 在第 12 页
- A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes · Biometrics · 2020-08-08 · 在第 12 页
- Sample size calculation for cluster randomization trials with a time‐to‐event endpoint · SiM · 2020-07-30 · 在第 13 页
- Adjusted win ratio with stratification: Calculation methods and interpretation · SMMR · 2020-07-29 · 在第 13 页
- Sample size calculation in three‐level cluster randomized trials using generalized estimating equation models · SiM · 2020-07-28 · 在第 13 页
- Bayesian methods for the analysis of early‐phase oncology basket trials with information borrowing across cancer types · SiM · 2020-07-27 · 在第 13 页
- Design and sample size considerations for valuation studies of multi‐attribute utility instruments · SiM · 2020-07-24 · 在第 14 页
- Relative efficiencies of alternative preference-based designs for randomised trials · SMMR · 2020-07-23 · 在第 14 页
- Decision-making with multiple correlated binary outcomes in clinical trials · SMMR · 2020-07-16 · 在第 15 页
- Developing and testing high‐efficacy patient subgroups within a clinical trial using risk scores · SiM · 2020-07-14 · 在第 15 页
- Empirical use of causal inference methods to evaluate survival differences in a real‐world registry vs those found in randomized clinical trials · SiM · 2020-07-09 · 在第 15 页
- Homogeneity testing for binomial proportions under stratified double-sampling scheme with two fallible classifiers · SMMR · 2020-07-08 · 在第 15 页
- Mixed-effects models for the design and analysis of stepped wedge cluster randomized trials: An overview · SMMR · 2020-07-06 · 在第 15 页
- Spatial regression and spillover effects in cluster randomized trials with count outcomes · Biometrics · 2020-07-02 · 在第 16 页
- Optimality of testing procedures for survival data in the nonproportional hazards setting · Biometrics · 2020-06-24 · 在第 16 页
- Batch Bayesian optimization design for optimizing a neurostimulator · Biometrics · 2020-06-24 · 在第 16 页
- Maintaining the validity of inference in small‐sample stepped wedge cluster randomized trials with binary outcomes when using generalized estimating equations · SiM · 2020-06-23 · 在第 16 页
- The contemplated average success probability for normally distributed models with an application to optimal sample sizes selection · SiM · 2020-06-17 · 在第 16 页
- Optimal Alpha Spending for Sequential Analysis with Binomial Data · JRSSB · 2020-06-15 · 在第 16 页
- Adaptive Designs for Optimal Observed Fisher Information · JRSSB · 2020-06-15 · 在第 17 页
- Group sequential monitoring based on the maximum of weighted log-rank statistics with the Fleming–Harrington class of weights in oncology clinical trials · SMMR · 2020-06-10 · 在第 17 页
- The impact of misclassification on covariate‐adaptive randomized clinical trials · Biometrics · 2020-06-07 · 在第 17 页
- Innovative Strategies, Statistical Solutions and Simulations for Modern Clinical Trials · JASA · 2020-06-04 · 在第 18 页
- Randomization‐based interval estimation in randomized clinical trials · SiM · 2020-06-03 · 在第 18 页
- On permutation tests for comparing restricted mean survival time with small sample from randomized trials · SiM · 2020-05-20 · 在第 19 页
- Sensitivity analysis for clinical trials with missing continuous outcome data using controlled multiple imputation: A practical guide · SiM · 2020-05-17 · 在第 19 页
- A semiparametric Bayesian approach to population finding with time‐to‐event and toxicity data in a randomized clinical trial · Biometrics · 2020-05-07 · 在第 20 页
- Statistical properties of minimal sufficient balance and minimization as methods for controlling baseline covariate imbalance at the design stage of sequential clinical trials · SiM · 2020-05-04 · 在第 20 页
- Point and interval estimation in two‐stage adaptive designs with time to event data and biomarker‐driven subpopulation selection · SiM · 2020-05-03 · 在第 20 页
- Seamless phase 2/3 oncology trial design with flexible sample size determination · SiM · 2020-04-27 · 在第 21 页
- A surface-free design for phase I dual-agent combination trials · SMMR · 2020-04-27 · 在第 21 页
- Inference on Selected Subgroups in Clinical Trials · JASA · 2020-04-17 · 在第 21 页
- Sample size calculation and re-estimation based on the prevalence in a single-arm confirmatory diagnostic accuracy study · SMMR · 2020-04-16 · 在第 21 页
- Modelling the patient accrual with truncated Gaussian mixture distribution for the accurate estimation of sample size in survival trials · SMMR · 2020-04-13 · 在第 22 页
- A phase I‐II design based on periodic and continuous monitoring of disease status and the times to toxicity and death · SiM · 2020-04-07 · 在第 22 页
- Predictively consistent prior effective sample sizes · Biometrics · 2020-04-06 · 在第 22 页
- A new conditional performance score for the evaluation of adaptive group sequential designs with sample size recalculation · SiM · 2020-04-06 · 在第 22 页
- STRATOS guidance document on measurement error and misclassification of variables in observational epidemiology: Part 1—Basic theory and simple methods of adjustment · SiM · 2020-04-03 · 在第 22 页
- Imbalanced randomization in clinical trials · SiM · 2020-04-03 · 在第 22 页
- Estimation of treatment effects following a sequential trial of multiple treatments · SiM · 2020-03-23 · 在第 23 页
- Blinded sample size reestimation for negative binomial regression with baseline adjustment · SiM · 2020-03-23 · 在第 23 页
- A threshold linear mixed model for identification of treatment-sensitive subsets in a clinical trial based on longitudinal outcomes and a continuous covariate · SMMR · 2020-03-20 · 在第 23 页
- Performance of propensity score matching to estimate causal effects in small samples · SMMR · 2020-03-18 · 在第 23 页
- Bayesian cluster hierarchical model for subgroup borrowing in the design and analysis of basket trials with binary endpoints · SMMR · 2020-03-17 · 在第 24 页
- Sample size and power calculations for open cohort longitudinal cluster randomized trials · SiM · 2020-03-04 · 在第 24 页
- An improved one-sample log-rank test · SMMR · 2020-03-04 · 在第 24 页
- A bootstrap semiparametric homogeneity test for the distributions of multigroup proportional data, with applications to analysis of quality of life outcomes in clinical trials · SiM · 2020-02-25 · 在第 25 页
- Experimental design and sample size considerations in longitudinal magnetic resonance imaging-based biomarker detection for multiple sclerosis · SMMR · 2020-02-19 · 在第 25 页
- A hierarchical testing approach for detecting safety signals in clinical trials · SiM · 2020-02-12 · 在第 25 页
- Adaptive multiarm multistage clinical trials · SiM · 2020-02-11 · 在第 25 页
- PA‐CRM: A continuous reassessment method for pediatric phase I oncology trials with concurrent adult trials · Biometrics · 2020-02-10 · 在第 26 页
- Highly efficient stepped wedge designs for clusters of unequal size · Biometrics · 2020-02-03 · 在第 26 页
- Sample size estimation for stratified individual and cluster randomized trials with binary outcomes · SiM · 2020-01-31 · 在第 27 页
- On powerful exact nonrandomized tests for the Poisson two-sample setting · SMMR · 2020-01-31 · 在第 27 页
- Analysis of counts for cluster randomized trials: Negative controls and test‐negative designs · SiM · 2020-01-30 · 在第 27 页
- A threshold‐free summary index for quantifying the capacity of covariates to yield efficient treatment rules · SiM · 2020-01-30 · 在第 27 页
- Bayesian leveraging of historical control data for a clinical trial with time‐to‐event endpoint · SiM · 2020-01-27 · 在第 27 页
- A causal framework for classical statistical estimands in failure‐time settings with competing events · SiM · 2020-01-27 · 在第 27 页
- Is the R coefficient of interest in cluster randomized trials with a binary outcome? · SMMR · 2020-01-23 · 在第 28 页
- Complier Stochastic Direct Effects: Identification and Robust Estimation · JASA · 2020-01-23 · 在第 28 页
- A fully Bayesian mixture model approach for identifying noncompliance in a regulatory tobacco clinical trial · SiM · 2020-01-21 · 在第 28 页
- A note on the bias of standard errors when orthogonality of mean and variance parameters is not satisfied in the mixed model for repeated measures analysis · SiM · 2020-01-09 · 在第 28 页
- Systematic analysis of the number needed to treat · SMMR · 2020-01-06 · 在第 28 页
- Power analysis for cluster randomized trials with multiple binary co‐primary endpoints · Biometrics · 2020-01-02 · 在第 29 页
- Sensitivity analysis for subsequent treatments in confirmatory oncology clinical trials: A two‐stage stochastic dynamic treatment regime approach · Biometrics · 2020 · 在第 31 页
- Neyman-Pearson classification: parametrics and sample size requirement · JMLR · 2020 · 在第 32 页